Marshall Wace North America’s Myriad Genetics MYGN Stock Holding History

Marshall Wace North America’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-43,441	Closed	-$566K	–	1478
2020 Q3	$566K	Sell	43,441 -65,999	-60%	-$835K	﹤0.01%	942
2020 Q2	$1.24M	Buy	+109,440	New	+$1.55M	0.01%	706
2019 Q3	–	Sell	-74,267	Closed	-$2.06M	–	1456
2019 Q2	$2.06M	Buy	74,267 +73,132	+6,443%	+$2.07M	0.01%	559
2019 Q1	$38K	Sell	1,135 -142,802	-99%	-$4.35M	﹤0.01%	1307
2018 Q4	$4.18M	Buy	+143,937	New	+$5.18M	0.04%	274
2018 Q2	–	Sell	-129,466	Closed	-$3.83M	–	1581
2018 Q1	$3.83M	Buy	+129,466	New	+$4.38M	0.02%	629
2017 Q4	–	Sell	-119,017	Closed	-$4.29M	–	1522
2017 Q3	$4.29M	Buy	+119,017	New	+$3.39M	0.03%	590
2013 Q4	$2.64M	Buy	+125,799	New	+$3.18M	0.06%	254

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace North America's MYGN Position: Q4 2020 in Review

Marshall Wace North America sold out of Myriad Genetics (MYGN) in Q4 2020, closing a stake of 43,441 shares — an estimated $566K sold.

Marshall Wace North America first reported a position in MYGN in Q4 2013 and held it in 8 quarters. The position peaked at $4.29M in Q3 2017. 187 funds tracked by Wall St. Rank hold MYGN as of Q4 2020.

Marshall Wace North America reported no remaining Myriad Genetics position as of Q4 2020 after selling out during the quarter.
Marshall Wace North America sold 43,441 Myriad Genetics shares in Q4 2020, an estimated $566K.
Marshall Wace North America first reported a position in Myriad Genetics in Q4 2013 and held it in 8 quarters.
Marshall Wace North America's Myriad Genetics position peaked at $4.29M in Q3 2017.
187 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.